Compare Raytheon Technologies Corp (RTX) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raytheon Technologies Corp vs Sana Biotechnology Inc — how do they compare? Raytheon Technologies Corp trades at $184.32 (market cap $248.42B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Raytheon Technologies Corp is far larger — about 296.9× Sana Biotechnology Inc's market cap, and Raytheon Technologies Corp pays a 1.58% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Raytheon Technologies Corp for 78 Days and Sana Biotechnology Inc for 23 Days on average.
| RTX | SANA | |
|---|---|---|
Market Cap | $248.42B | $836.71M |
Volume | 4,380,368 | 4,507,444 |
Sector | Industrials | Health |
52-Week High | $225.49 | $5.92 |
52-Week Low | $157.00 | $2.68 |
Typical Hold Time | 78 Days | 23 Days |
Enterprise Value | $278.97B | $749.96M |
Dividend Yield | 1.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RTX trades at $180.26, down 1.65% today, amid a bearish technical signal but strong fundamental performance. The company reported three consecutive quarterly earnings beats, with Q3 2026 EPS expected at $1.77. Revenue grew to $88.6B in 2025, with net income margin improving to 7.59%. Analyst consensus remains strongly bullish with a $236.27 price target and 65% buy ratings, supported by a $289B backlog and defense sector tailwinds.
The outlook for RTX is positive given robust defense spending, earnings momentum, and analyst confidence. Risks include execution on large contracts, debt levels, and geopolitical uncertainties. The stock offers growth potential with a 30% upside to consensus target, but investors should monitor quarterly execution and defense budget developments.
SANA Biotechnology trades at $2.72, down 1.09% with a bearish technical signal despite bullish oscillators. The company shows significant financial challenges with negative revenue, a net loss of $244.17 million in 2025, and negative cash flow. However, analyst sentiment remains positive with 82% buy ratings and recent conference presentations highlighting ongoing research in engineered cell therapies.
The outlook is highly speculative given the pre-revenue stage and substantial losses. Investment opportunity lies in the potential of SANA's biotechnology platform, but risks include cash burn, clinical trial outcomes, and competitive pressures. Wall Street maintains cautious optimism despite fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
